Pfizer and Lilly announce top-line results from second Phase 3 study of tanezumab in osteoarthritis pain

Alternative Medicine
PfizerPfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced positive top-line results from a Phase 3 study evaluating tanezumab 2.5 mg or 5 mg in patients with moderate-to-severe osteoarthritis (OA) pain. The tanezumab 5 mg treatment arm met all three co-primary endpoints at 24 weeks, demonstrating a statistically significant improvement in pain, physical function and the patients’ overall assessment of their OA compared to those receiving placebo.

Leave a Reply

Your email address will not be published. Required fields are marked *